Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
June 23, 2022 07:24 AM EDT
R&D

No­var­tis pledges $250M in R&D fund­ing for ne­glect­ed trop­i­cal dis­eases, malar­ia

Amber Tong

Over the next five years, No­var­tis is pledg­ing to pour $250 mil­lion in­to R&D for new treat­ments of ne­glect­ed trop­i­cal dis­eases and malar­ia — with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times